Burning Rock Biotech (BNR) to Release Quarterly Earnings on Tuesday

Burning Rock Biotech (NASDAQ:BNRGet Rating) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 31st. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Burning Rock Biotech (NASDAQ:BNRGet Rating) last issued its quarterly earnings results on Monday, March 21st. The company reported ($0.38) EPS for the quarter. Burning Rock Biotech had a negative return on equity of 37.96% and a negative net margin of 156.90%. The business had revenue of $23.12 million for the quarter. During the same period last year, the company posted ($0.23) EPS. On average, analysts expect Burning Rock Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:BNR opened at $3.00 on Tuesday. Burning Rock Biotech has a one year low of $2.87 and a one year high of $37.50. The company has a 50 day moving average of $7.01 and a 200-day moving average of $9.25. The stock has a market cap of $315.33 million, a price-to-earnings ratio of -2.47 and a beta of -0.33.

Hedge funds have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech in the fourth quarter worth $83,000. Jane Street Group LLC bought a new stake in Burning Rock Biotech during the first quarter worth $97,000. Renaissance Technologies LLC bought a new stake in Burning Rock Biotech during the third quarter worth $181,000. Invesco Ltd. raised its position in Burning Rock Biotech by 60.3% during the first quarter. Invesco Ltd. now owns 60,609 shares of the company’s stock worth $563,000 after acquiring an additional 22,805 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Burning Rock Biotech by 2.4% during the third quarter. Bank of New York Mellon Corp now owns 36,174 shares of the company’s stock worth $647,000 after acquiring an additional 860 shares in the last quarter. 45.05% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research cut shares of Burning Rock Biotech from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 22nd.

Burning Rock Biotech Company Profile (Get Rating)

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Further Reading

Earnings History for Burning Rock Biotech (NASDAQ:BNR)

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.